Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Study of Duvelisib and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma or Patients With Richter's Syndrome

Trial Profile

A Phase I/II Study of Duvelisib and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma or Patients With Richter's Syndrome

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Duvelisib (Primary) ; Venetoclax (Primary)
  • Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Richter's syndrome
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Dec 2019 Results (n=12), presented in a Verastem Oncology media release.
    • 12 Nov 2019 Planned number of patients changed from 47 to 67.
    • 06 Nov 2019 Results (n=12) (data cutoff July 12, 2019) of Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma has released at the 61st Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top